Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Gain Therapeutics Inc (GANX)

Gain Therapeutics Inc (GANX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Gain Therapeutics Inc 4800 MONTGOMERY LANE SUITE 220 BETHESDA MD 20814 USA

www.gaintherapeutics.com P: 301-500-1556

Description:

Gain Therapeutics Inc. is redefining drug discovery with its See-Tx(TM) target identification platform. It involved in identifying and optimizing allosteric binding sites which have never before been targeted. The company is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain Therapeutics Inc. is based in BETHESDA, Md.

Key Statistics

Overview:

Market Capitalization, $K 51,448
Enterprise Value, $K 40,228
Shares Outstanding, K 18,052
Annual Sales, $ 60 K
Annual Net Income, $ -22,270 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -4,720 K
EBIT, $ -22,260 K
EBITDA, $ -22,180 K
60-Month Beta 0.52
% of Insider Shareholders 11.00%
% of Institutional Shareholders 11.97%
Float, K 16,066
% Float 89.00%
Short Volume Ratio 0.34

Growth:

1-Year Return -47.27%
3-Year Return -70.34%
5-Year Return 0.00%
5-Year Revenue Growth 200.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.29 on 03/26/24
Latest Earnings Date 05/10/24 [--]
Earnings Per Share ttm -1.71
EPS Growth vs. Prev Qtr 21.62%
EPS Growth vs. Prev Year 25.64%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

GANX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -193.03%
Return-on-Assets % -123.21%
Profit Margin % -37,116.67%
Debt/Equity 0.05
Price/Sales 971.53
Price/Cash Flow N/A
Price/Book 3.01
Book Value/Share 0.97
Interest Coverage -1.06
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar